CT-scan of upper mediastinum when the tumor progressed after two cycles of VIDE

<p><b>Copyright information:</b></p><p>Taken from "Midline carcinoma with t(15;19) and fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy"</p><p>BMC Cancer 2006;6():69-69.</p><p>Published online 16 Mar 2006</p><p>PMCID:PMC1456975.</p><p>Copyright © 2006 Engleson et al; licensee BioMed Central Ltd.</p> Tumor masses almost surrounds the superior vena cava (with the stent) and right upper lobe bronchus. At the autopsy four weeks later, there was only a tiny focus of tumor left in conjunction with the cava stent

Fluorecense in situ hybridization: a) Metaphase FISH of the t(15;19) showing one green (15q14) and one red (19p13) signal on the normal homologues

<p><b>Copyright information:</b></p><p>Taken from "Midline carcinoma with t(15;19) and fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy"</p><p>BMC Cancer 2006;6():69-69.</p><p>Published online 16 Mar 2006</p><p>PMCID:PMC1456975.</p><p>Copyright © 2006 Engleson et al; licensee BioMed Central Ltd.</p> The 15q14- and the 19p13-specific BAC probes were both split by the translocation and therefore visualized as a red-green (yellow) fusion signals on der(15) and der(19), respectively. b) Interphase FISH. Yellow arrows indicate fusions

Tumor section (H&E) shows loosely arranged medium-sized cells with finely dispersed chromatin, solitary nucleoli and clear, often vacuolated cytoplasm

<p><b>Copyright information:</b></p><p>Taken from "Midline carcinoma with t(15;19) and fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy"</p><p>BMC Cancer 2006;6():69-69.</p><p>Published online 16 Mar 2006</p><p>PMCID:PMC1456975.</p><p>Copyright © 2006 Engleson et al; licensee BioMed Central Ltd.</p> The upper left inset depicts PAS-positive cytoplasmic glycogen granules, while the middle inset shows strong epithelial membrane antigen expression in all tumor cells. The lower inset includes the single field which expressed the broad spectrum cytokeratin marker MNF116

RBM3 staining distribution in non-seminomatous germ cell tumour (NSGCT) denoted as nuclear score (fraction × intensity).

<p>(A) mean score, (B) highest score and (C) lowest score. RBM3 staining distribution according to CS I and CS > 1 on (D) mean score, (E) highest score and (F) lowest score. Boxplots shows the five statistics (minimum, first quartile, median, third quartile, and maximum). P-values refer to Mann Whitney U test for comparison of medians.</p

Cox univariate and multivariate analysis of failure free survival according to RBM3 expression in patients with metastatic non-seminomatous testicular cancer.

<p>* Multivariable analysis on tumor marker status and non-pulmonary visceral metastasis.</p><p>Tumor markers (AFP, HCG, LDH) as continuous variables.</p><p>Cox univariate and multivariate analysis of failure free survival according to RBM3 expression in patients with metastatic non-seminomatous testicular cancer.</p

Association between clinicopathological characteristics in 206 patients with non-seminomatous testicular cancer and RBM3 expression.

<p>^↑Nuclear score < = 0.5</p><p>^↓Nuclear score > 0.5</p><p>^‡ According to ICCCGC</p><p>*Patients with CS>1</p><p>Abbreviations: AFP, α-fetoprotein; β-HCG, β–human chorionic gonadotropin; LDH, lactate dehydrogenase; NPVM, non-pulmonary visceral metastasis.</p><p>Association between clinicopathological characteristics in 206 patients with non-seminomatous testicular cancer and RBM3 expression.</p

Cox univariate and multivariate analysis of failure free survival according to RBM3 expression in patients with metastatic non-seminomatous testicular cancer.

<p>* Multivariable analysis on tumor marker status and non-pulmonary visceral metastasis.</p><p>Tumor markers (AFP, HCG, LDH) as categorical variables. The cut points defined in the IGCCC are used.</p><p>Cox univariate and multivariate analysis of failure free survival according to RBM3 expression in patients with metastatic non-seminomatous testicular cancer.</p

Sample images (10X magnification) of immunohistochemical RBM3 expression in different tissue entities from four cases.

<p>Case 1—column 1: atrophic testis; column 2–4: embryonal carcinoma with negative RBM3 expression (note positive stromal lymphocytes). Case 2—column 1: intratubular germ cell neoplasia (ITGCN); column 2–4: embryonal carcinoma with <10% seminoma (column 2) with best score 12 and worst score 2. Case 3—column 1 normal testis; column 2–4: tumour with components of embryonal carcinoma, immature teratoma and yolk sac tumour with best score 12 and worst score 8. Case 4—column 1 normal testis; column 2–4: tumour with predominant seminomatous histology (~80%) admixed with teratoma (not represented in the TMA), best score 12 and worst score 8.</p

Failure-free survival of patients with non-seminomatous testicular cancer according to RBM3 expression.

<p>(A) 118 patients with clinical stage 1, (B) 88 patients with metastatic disease and (C) 206 patients with clinical stage I to IV and Mk+.</p

Additional file 1: of Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

Supplementary material and methods. (PDF 198 kb